| 不可手术切除的食管癌同步放化疗进展 |
| |
| 引用本文： | 刘亚男1,' target='_blank'>2,贾鑑慧1,' target='_blank'>2. 不可手术切除的食管癌同步放化疗进展[J]. 现代肿瘤医学, 2019, 0(13): 2411-2414. DOI: 10.3969/j.issn.1672-4992.2019.13.042 |
| |
| 作者姓名： | 刘亚男1 ' target='_blank'>2 贾鑑慧1 ' target='_blank'>2 |
| |
| 作者单位： | 1.中国医科大学，辽宁 沈阳 110000;2.中国医科大学肿瘤医院，辽宁省肿瘤医院，辽宁 沈阳 110000 |
| |
| 摘 要： | 食管癌起病隐袭，早期诊断率低，发现时绝大部分已失去手术机会，放疗或化疗生存率也不乐观。近年研究表明，对于不可手术切除的食管癌，同步放化疗成为标准治疗方式。我国食管癌以鳞癌为主区别于欧美国家，研究适合于我国食管癌特点的同步放化疗方案尤为重要。本文就近年来不可手术切除的食管癌同步放化疗的新进展做一综述。
|
| 关 键 词： | 食管 不可手术切除 同步放化疗 |
New advances in the concurrent chemoradiotherapy of unresectable esophageal carcinoma |
| |
| Liu Yanan1,' target='_blank'>2,Jia Jianhui1,' target='_blank'>2. New advances in the concurrent chemoradiotherapy of unresectable esophageal carcinoma[J]. Journal of Modern Oncology, 2019, 0(13): 2411-2414. DOI: 10.3969/j.issn.1672-4992.2019.13.042 |
| |
| Authors: | Liu Yanan1 ' target='_blank'>2 Jia Jianhui1 ' target='_blank'>2 |
| |
| Affiliation: | 1.China Medical University，Liaoning Shenyang 110000，China；2.China Medical University Cancer Hospital，Liaoning Cancer Hospital，Liaoning Shenyang 110000，China. |
| |
| Abstract: | Esophageal carcinoma is a malignancy with a poor prognosis.Most patients with locally advanced esophageal cancer either not candidates for surgical treatment or prefer not to undergo surgery.Survival rate of radiation therapy or chemotherapy is low.Recent researches have shown that concurrent chemoradiotherapy is the standard therapeutics for unresectable esophageal carcinoma.The mainly pathological type of esophageal cancer in China is squamous cell carcinoma which is different from Western countries，so it is very important to study the therapeutic regimen which is suitable for the patients with esophageal cancer in China.This article reviews the recent advances in the concurrent chemoradiotherapy of unresectable esophageal cancer. |
| |
| Keywords: | esophageal carcinoma unresectable concurrent chemoradiotherapy |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载免费的PDF全文 |
